<SEC-DOCUMENT>0001193125-15-399317.txt : 20151210
<SEC-HEADER>0001193125-15-399317.hdr.sgml : 20151210
<ACCEPTANCE-DATETIME>20151210060234
ACCESSION NUMBER:		0001193125-15-399317
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20151210
FILED AS OF DATE:		20151210
DATE AS OF CHANGE:		20151210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		151279624

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d40080d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 10 December 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">429 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting CEO</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9&nbsp;December 2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN APPOINTS DR JAMES GARNER AS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHIEF EXECUTIVE OFFICER</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 10&nbsp;December 2015 </B>&#150; US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr
James Garner as Chief Executive Officer. Dr&nbsp;Garner will take up the role on 1&nbsp;February 2016, at which time he will be appointed to the Board of Directors of Novogen.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Garner, 42, brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical
sector. His previous responsibilities have included leading non-clinical safety and efficacy, phase I-IV clinical trials, product registration, reimbursement, medical marketing and business development.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Garner is currently Head of the Unit Development Office, AP R&amp;D with Sanofi and is
based in Singapore. He will relocate to Sydney in the New Year.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After qualifying in
medicine at Imperial College in London, Dr Garner spent several years as a practicing clinician in the UK and Australia before joining Bain&nbsp;&amp; Company, a global management consulting company in 2002. He subsequently worked with Biogen and
Progen Pharmaceuticals in Australia and with Quintiles, an international clinical research organisation in Singapore.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In 2009, he was appointed Regional Vice President for Takeda Pharmaceutical Company with overall responsibility for all clinical development activities and
registration of new chemical entities in the Asian region (excluding Japan), and served as General Manager of the company&#146;s regional R&amp;D Hub in Singapore. In mid-2013, Dr Garner took up his current role at Sanofi.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from his medical qualifications, Dr Garner holds a BSc (with First Class Honours) from University College London, an MA
in Philosophy and an MBA from the University of Queensland, and a postgraduate qualification in Applied Finance&nbsp;&amp; Investment from the Financial Services Institute of Australasia. In 2008, he was named a &#145;Young Executive of the
Year&#146; by the <I>Australian Financial Review</I>&#146;s <I>BOSS</I> Magazine. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg03b.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In announcing the appointment, Novogen&#146;s Interim Chairman, Ian Phillips welcomed Dr Garner to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;James is joining Novogen at an exciting time and he brings a wealth of relevant experience from the international pharmaceutical and biotech sector. I
am confident as CEO, he will lead us through the next stage of the Company&#146;s development and achieve both our short and long term goals,&#148; Mr Phillips said. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Also I would like to take this opportunity to thank Iain Ross for the significant contribution he has made over the past 5 months as Acting CEO by
ensuring that the Company is well-placed to progress our lead candidates through to the clinic in 2016/17. Mr Ross has led the initiative to identify and successfully recruit James Garner as our new CEO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biographical Summary of Dr Garner
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Garner, MA, MBA, MBBS, BSc (Hons) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Age: 42 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citizenship: UK&nbsp;&amp; Australia </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Academic
Qualifications </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master of Business Administration &#150; University of Queensland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2001</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master of Arts (Philosophy) &#150; University of Queensland</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1997</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bachelor of Medicine &amp; Bachelor of Surgery &#150; Imperial College</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1994</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bachelor of Sciences (First Class Honours) - University College London</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered Medical Practitioner with the General Medical Council of Great Britain </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Professional Career </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2013&nbsp;&#150;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Head, Unit Development Office, Asia R&amp;D with Sanofi (Singapore)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2009&nbsp;&#150; 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President &amp; General Manager, Takeda Pharmaceutical Company (Singapore)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2009</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regional Medical Officer with Quintiles (Singapore)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2007 &#150; 2008</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Clinical &amp; Medical Affairs with Progen Pharmaceuticals (Brisbane)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2004 &#150; 2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Medical Manager with Biogen (Sydney)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2002 &#150; 2003</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Corporate strategy consultant with Bain &amp; Company (Sydney)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1997 &#150; 1999</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hospital physician</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg03b.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Key Terms of the Executive Employment Agreement Between Novogen And Dr Garner </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Position and Commencement Date </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company appoints Dr
Garner as CEO starting on 1&nbsp;February 2016. On commencement, he will be appointed to the Board of Directors of Novogen and other group companies (which may also include committees to the Board). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Remuneration </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Base salary<B>:</B> A$400,000 per annum (not including superannuation). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Performance bonus: each year Dr Garner may receive a performance bonus valued at up to 30% of his Base Salary (given at the discretion of the Board, and measured against the key performance indicators in place for the
relevant year). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Subject to any necessary approvals, Dr Garner will be entitled to participate in the Novogen Executive Share Option Plan (<B>ESOP</B>) in accordance with the rules of the scheme, corporate laws and relevant
listing/stock exchange rules. Under the ESOP, Dr Garner will be granted options over 7.5&nbsp;million shares which will vest in tranches over 4 years. The exercise prices are calculated by adding a 45% to 90% premium to the 30 day Volume Weighted
Average Price (VWAP) to the close of business on 11&nbsp;December 2015. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Termination </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The employment agreement may be terminated by either Novogen or Dr Garner by providing 6 months&#146; notice. Novogen may elect for the termination to take
effect earlier by making a payment in lieu of notice or may direct Dr Garner to take leave in that period. Dr&nbsp;Garner&#146;s employment may also be terminated in instances of serious misconduct, if he fails to carry out his duties or is
incapacitated for an extended period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Restrictive Covenants </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Australia and New Zealand for a period of up to 12 months after his employment ends, Dr Garner will be restrained from: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being engaged by a competitor to Novogen&#146;s business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">soliciting Novogen business or employees away from Novogen. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen
Group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)] yielding drug candidates that are first-in-class with potential
application across a range of oncology indications. Given the encouraging data from <I>in vitro</I> and <I>in vivo</I> preclinical proof-of-concept studies in the field of oncology, the Company&#146;s immediate focus is to undertake the respective
toxicology programs. The target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. While the initial target pediatric indication for Anisina has been identified as neuroblastoma, Novogen is yet to
identify the adult indication and is intending to open an all-comers Phase 1 trial initially based on its preclinical studies. For more information, please visit <U>www.novogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg03b.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Director, Novogen Group
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com /</U> Ph: +61 (0)&nbsp;2 9472 4109 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release
contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such
words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148;
&#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#146;s drug development program, including, but not limited to, Cantrixil, Anisina, Trilexium, and any other statements
that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production
and marketing of the Company&#146;s drug components, including, but not limited to, Cantrixil, Anisina, Trilexium, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Cantrixil, Anisina, Trilexium, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual
property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil, Anisina, Trilexium, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission
including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties
mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40080tx_pg03b.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g40080tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40080tx_pg03a.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
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MXQ]!M^#O6+F4A)\E[J?2_0R^JQR7% * 4 H!0"@% 759/U-S\\O\EJ@):@%
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MJD'5.O D<0=.H\* N*@% 5'0?-\(H >D^<^_0%* 4 H!0"@% * 4 H!0"@%
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M(GXE^3E+TL\%>BTM#R3OU20>QL_!50RRSTGSFJ I0"@% * 4 H!0"@% * 4
MH!0"@% =K,A^.XV]'><8>:4%-.M+4VZVH=!0M!"DGS4:35'JBL6X2YX-J2Z4
M9FQ+=&2'6+=DBD/,.*2VFZA/*^RHGE2J:E.C;K7'BL *3TG6H^_B*G/:^0V?
M;M_FIJSG=Z+=.?I755+BO3Q,[<" 004GBD@@@@\001P.HJ/-M% * 4 H"ZK)
M^IN?GE?DM'X* EJ 4 H!0"@% * 4 H!0"@% 1ERZ&?.OWDT!%4 H!0"@*$@#
M4G04!T+?Z>0:>7X@: Z"2>).M 8DN?[1G_VR1^E569'V5V&LW_Q,^U_2>&O1
MY% 1=]_8EU_L$K]$:NV?:]9BYOX.[_+E]#->ZE31!0"@% * 4 H!0"@% * 4
M H!0$5>+):K]$5"NT%F:R=2GO$_2M*/#G8>20ZRL=1217NW.=J7-;;4C$S,'
M&SK3LY,%.'IXKTI\5ZC<'$+2BW8?BT*(5JCP\?M49D.$+=#;,-E".=6B0L\H
MXGAK4%?DYWYSE[3DW\NIU?:L>.-M6-9M>S"Q!+KTBJ?,3?61UCIJU6I("@+B
MLWU#_P"=3^0:M7/:]1DV.#)>K9D"@).U?K/^PKWJ N6@% 5'0?-\(H >D^<^
M_0%* 4 H!0"@% * 4 H!0'%:BA"UCB4-K6!Y4(*A[U%Q*2;46UQ2-)I4AV9*
MDRY"BM^3(=D.K4227'5J6HZGIT)X5/I**48\$CEUR3N7)7).LI-OY6=-5/ H
M#J>;#K3C9Z%H4G[X.A^_50RR'6UM.*0L:*2H@CS=?F(H$==4 H!0"@% * 4
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M\Y+R?YLP\/!O9-EO%G9=RD[T.\[,_$E+6<%)VZ4;E%QUYE3[;US<^S!0"@%
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MXR4]QW#+X5J2X1P-= 8G\,3_ (O-VMK-B-[LOW_VY]A;BX9@VX>1X+:_#HQ
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M]1XC,8?1IU7UN*T*_N'YH\U81LQZ: 4 H!0%1T'S?"* 'I/G/OT!2@% * 4
MH!0'%:VVFW'GG&V66D%QUYU:&FFFT\5....*2AM"1TDD 4U;HN(;44Y2:44J
MMO@EZ35O<CQ1XOC/K%LPMMK+;TCF;5.YU-X]"<XI.LA!#MU<0KYK7*V3P[RI
M;%VJ[<I.^^2WU=/^1SW??B!M^ WC[6EDY/#FK_#B^W1SIU1-$LPSS+,]N)N6
M4WF3<G$J48T8D,VZ"DGZN# :Y8\= '#4 K5IZ2C4]9QK6/'DM))?/ZV<CW/=
M]QWB_P"/N%V5Q]$:TC'T1CP2^?K;+1J^1IZ(EPGVI]-PMDV7;I\5+CD>9"D.
MQI+*@A7%MYE2%IUZQKH1P-4E"$URS58]1[MWKV/-7\><H7HUI*+HT=N ^)B9
M$[FVY_&7/8!0VG(;>T!.;3T!5P@H"6I:4_.6SRN=?*HU7(VR+=<=I/J?U&;M
M/G6Y::Q]V3E#AXD5JOVEZ>M?(;>62_6;(X#5TL-RB76 [\F3#=2XE"M->Z>1
MP<8>3UH6E*AV5#SA.W+EFFI>DZ%BYF-FVU>Q)QN6GTI\/0^I^ADO7@R10"@%
M * X+0EQ)2L!23P*2 0?N$&@H0LJSI5JJ,>4@$]THGE/XJOF_=HBG @'67&5
MEMQ"D+'41[H[10J== * 4 H!0"@% * 4 H!0%4I4I02$J*E< E()43Y!TF@J
M;?[46=:\-M;DG5""_</HQ\L_UQ[Y6NH2#]^HC+^_EZC?MA_M</VI?O,RZTRT
MPGD90EM/8D<3Y5*Z5&L8ESY[?:>^&R]>)7PK9):L3<N#V;;93T[IXK9(DAT1
M\I=QZW3F;UCK\)*@S,G3+!+D+MY4"I$QI"4Z=XK7;?)>\6]GWR$[R7N]Y>')
MM:QYFN62ZES44O0_0?/_ .9;X>9GQ#^&-^QM;N/=]MN>^6;<6TKWAPDKEN4:
MTE)VI2=JM6KB27M,_%MZRQR\W>)Z-0DZAS7^;W?R^?7ARZ<VO#36OHNC:>FA
M^/;G%:55>KI[*=?H-_<PW,R;PL[=;>^'O'XN'W3.$.2=X=Y49U@N&[CQ<.S/
M<*S69O'MNK#;<VLU]@XY<<<P6WP7[\N*VT](NDTL.J/JB0-5Q\.UO>7>W:ZY
MQQ72U9Y)SM\\(2?-<?)*/,I7&^2KTBJKVCNF[>8MP^&GE_ \A8,,.[O2<L[<
M/><;'RU8R<FW;\/$M1R+=R-F=K'A"61R)2E>N.$F_"27;M?O'DGB.M>=^&;,
MF\!Q^X;NVVT2-K[SAFWN![8(=W@P67*ON#XEE<G";%8$WS'<]4])M+;4XNM1
M+K)AR$<JD*)9NW6=HNVMYQ_%E#';\53G.Y2U/NSG'GE+E=M4DW'5QYD5\M^;
M=P^(&+G?#G=8X&/?W:%N6'<Q\7&PZYV-*5S&L7WCVK7B6<BL[*5RL;=Z=J:H
MTV:!RN:"_)B3T+@S(+[\6=#F),>5"EQ'5LRXLMAS1QB1%>;4AQ"AS)4D@\16
MU1?-!3CK%JJITUX4[>@X9<3LW)6;R=N]"3C*,E249)T::XIIK5<3]$VQOAMO
M&QGV0GBNSS+EW"'DV_FULW.58_+>?;B6'#X346+AQ<M[B@RQ>+Y;Y*YLAPI#
MG</L-'ZO2N!>?MYM;EO2Q['*[.*G#F7VI?;UZDZ)=C?2?J]^4WX=YODKX=O>
M]U=R.Y[Y.&3X4FTK6.H4Q^YP5RY%NY*5*\LH1?LT-R_&4/\ ^<9D'Q7P$JB[
M;[I;$3?#3XGFV4+]5@L7?![HQL)NY.;:2H!>)YA/5C\Z01JFW75KF.C8TT:.
MNA]2%D[89+$\.;W@2\2.>HD6_8_-_ GM_P"'7<+/VXLF99]J<MANV#/MO[YF
M;L-I]=DPW*%R)MO<N2P(L66AKOEI2L&CZO2#-'C%WYVLWSV7RCPO["Y[AV\V
M\/B.ML3;?'[!MQ?;;FT?%L:R&XV].6;F9S<<>?N%NQ3#\.QM$B6J1-=9,A]+
M3+ 6XL 42IJ^ ,5>*/=!C[/[?R^[TQ$NR<6\0OA7NFWUMCE*_P#YKQ/>'JUM
ML;-,%"00N\9[BV0B"D'TW50-/FZ55:^H'JN^T%U\'>TOV?\ NA<+7>\FMGA?
MNV7.>)=^P6Z7>[Y%C>(K$)<;=3=9=I@-/W&ZLXGN-<$2;B&FW'D6Y;K@!2V:
M+6JZP;-;O^-_P[0MK+Z[MGNA@^]NX.;XU=;!M3M9M7D5KSC-=P\MR*V2;7C]
MHA8_8WYMP@0%SI:%3Y<UN/%@14N./K1R$52FM&#5#9B!'^SGW(PN%O[<4V3:
MG=KPN^'G;.;O(MF2_@6#;Z;%6>\6.\89F5\89=CXQ9\HM-_[ZSSI7=PW78RV
MRM*M*JWS:H&Q62^*O&]QM[+KL_M-N3MEN/MU.\'>_6XV72\)OEDRZ;:<QLDR
MRV/&8\N]6.XS6;5$F6:\2U^JNI"Y!2%@Z(-4!KCX!8/@J@[1>$V[Q?$!&7O3
M_P!.-M2G!I/BQRZ:TK.)N.1(C^/#:25N$[82X)DA32+1[.[II8"4,@I !O7T
M NO'MD96_P!M]]H+AF.W!%BW*L7CPSG<+9O+$Z)?Q#>3 \4VTOF!W@/)])N*
M]<F/4)R=='+?,>0?15I1@]_@ WCC^(W>'Q?;H^SG,?R*XPO#'9L\Q22AQJ7A
MNY>*;97O&=Q,/FMN(2MMVQY7:Y+2"1HID(6-0K6JR5%0'TR<:<:5RK24GJU'
M3Y0>@BO(.% * 4!XG/EJ\] <* 4!B6Y_M&?_ &R1^E569'V5V&LW_P 3/M?T
MGAKT>2A( *E$)2D:J4H@)2!Q)43H  *4Z VDJO1&.<JRR&N(_:[<OUAU\=U(
MDH_5VVM1SMMK(^E<7IIJGT0->)K,LV)<RE+V$S7=SW2W*W+&QWS2EHVN"7UF
M+JSC7!0"@% * 4 H!0"@% * 4 H!0"@% 8GWG_@YO_&H'Z*76?MWXC_:S5_-
MW]KC_.C]$C5JIDYF?43P#?P/N#_J^W_Y$BM2\Q_?V_V/^X[_ /!S^U9W_)A^
MXC?&M<.Q"@% * 4!4=!\WPB@!Z3YS[] 4H!0"@% * 4!H+XN<JOJ,EL^(LW&
M3'L!L#%TDV]AQ334Z;*FS6>>:$$>LH8:BI#:%:H3J3IJ:V+9[5OP976DY\].
MRB7#Y3CGQ)W#,]_M[;&;6'X*FXK3FDY27>ZTDM%PZ>)IQ4R<R% * X.?5._F
MG/R%55<3S+V7V&KU2CXLU*7M/M+WV[R2\XSEUBDV:>_$]:N]MASHZ'%>JSXD
MF8S'>8F1]>[>06G#H2-4G0@@U9R+<+MEQDEI%T9);/FY.%GVI8TW'FN1370T
MVDTUP?TGU.4-%*2 >!( Z] 2!Y3PK5J'>'1-KTLI0"@%4 H!0"@.AZ.U(3RN
MH"AU=H\QZ0: M^5:'4:K8U<3Q]#ASCS= 7K]PU4=!$*24D@@@CI!!U'G'DH#
MC5 * 4 H!0"@% * DXML>?T4L%IL_.4/2/'I0CAJ-.VJ@N./$8C !I.BM-"X
M22L]OI=0\@J@H;6[9?P;;?S]Q_OKM1.7]^_5]!OVQ?VN';+]YE_5BDN5!(((
M.A'0: MK]R\)YP[^Y&%!P+#@<&(8YWG.%<_><_LLJ+G/QUZ=>-7O><BGWESA
M^M+ZF1G]$V2O-[EA\W&O@6:UZZ\A^4+[6CPBW_:'Q(W#<S"\?OUYV]W[>N6:
M,+M5NN=Z_=_/>^0O.+#+7$8EN,,S)DE%RA\Y +4M;:>#) [IY#\P6<_:%A9$
MXQS,9\CJTN:'&$NA<-'Z5UL_+C\TOPIS_*?Q$N>8MHL7[NQ;XYY"Y8RN.WDU
M_P#)MR<5*E9M7;=='&;2]AF+?LW?"!D7B'\2^+IRW',AM&VNV#T+<7.IMQME
MULJ;@+-/9=QO%XDF5'BK5+O]]::#G=*YVX;+Z@00#6=YP\P6=JV:Y[O.,LN\
MG;C1ITYEWI=/!5I_J:-<_+O\)]Q\_?$;&_J>/?M>7=LE'*R93A.WS>').S9B
MVD^:[=4:TU5N-QZ.C/V)2,/PR4^_*D87AK\B2ZZ_(??Q/'7GGWGU*<>=>=<M
MJG'7'7%DJ4HE2B=22:^?8Y.1%<JN7:)4]N7Z3]:Y[-LMR;N7,+#E<DZMNQ9;
M;>K;;AJV]74F7X<.5$<@2H4.7 =9$9ZWRHD>1 >C )2(ST)YM<5R,$I [LH*
M- !IH*LZO5ZLD4E%*,4E%*B2T22X)+@DNA+1=!QEP8-PB/6^X08-PM\EL,R+
M?<(<:= D,I*5):?@RFG8K[25(20E:"D%((&H%"IS3$A)A^S4PH0MIC>HFVB)
M']FJ@\G=F"JW]UZFJ$6]$]R4=WRC333A0$-C^(XCB*);>)8CBN)HGJ"YR,7Q
MNRXZF:L*YPJ8+-!A"40HDCO.;0\: D9]JM-V1';N]HM-W;B26YL1%VMD&YHB
M36=>YF1$3F)"8LQK4\CK82XG7@H4!(A:DGF!(5Z6IU)U"AHH'7I"@2#KT@\:
M M>SX3A..W&7>,=PK#<>N\_G]>NU@Q2P66Z3>]XNB5<+9;HLR0'2=5!:R%'B
M: N"5&BSHLB!/BQ9\"8T69D"?&8FP9C*OE,RX<IMV-)95UI6E23V4!!6+#<,
MQ9N2SB^&XAC+,Q*DS&L<Q>Q6)N8E>H4F6BU0(B925 G4.!0X]% =,;!,#A26
M)L/ \&AS(KJ7XLR'AV-Q)<:0V>9M^-*CVQN1'?;5Q2M"DJ!Z#0%Q,18D54A4
M2)$B+ER%3)BHL9B,J;,<"$N3)BF6T*E3'4MI"G7"IQ02 3P% =$2UVN ]-D6
M^UVNWR+F_P"M7.1 MT*%(N<OTM9=R?BL-/7"4><_2/*6OB>/$T![%H2XGE6D
M*'8?@/2* C'X"AZ3*N8:?5J^4/Q2>!H"-*5 D$$$=((XB@*4!XG/EJ\] <*
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M?/U'IH5JZ4Z"BEK6-%*) .NA/#7S=%"GH.- * 4 H!0"@% * 4 H!0"@% *
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M&YEIP5NSS,;SK(VK1!NV8Y?CS=P3AV-M)SJZ7=J!C;;B[>VA+Z'G7$J2 V0
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M&[G:+'N_L#;;[OW*N5V3E7AR9O\ $M#3.5V&P69]B1=H-Y]45'FNJ)3&Y&@
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M/?:6E ^S)W**O11^XFS'\T:#][< Y0.;1.IZJYYY-T\Y6F^/BWG_ -,SZ_\
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M ]G;0$?0"@% * 4 H!0%%?(7^(O\DU5<2CX/L,(GI-9AK!2J@4 H!0"@% *
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%X10'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g40080tx_pg03b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40080tx_pg03b.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  Z L8# 1$  A$! Q$!_\0 S@ !  $$ P$!              4#! 8' 0((
M"0H! 0 " P$! 0             $!0$#!@('"!   0," 04)"0P' PP#
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M6UCTI<_Q*X_?JK[5-V.I#XM7WI;6/2ES_$KC]^JOM4W8ZD/BU?>EM8]*7/\
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MKFX>->I.?:WALT$!7#_X=1@/W9R ;@()R!>S1AD86L ( @" ( @" ( @" (
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M7NR\#1H]] 2,5FIF8&1SYCO'X#,G TEQQXT!+-:UC0UH#6M  :   !O (#E
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M'.K*4GU9+VLX*^_N7S*KC'E]"E2CKFW.7_+'P9HW:+MB[3MJ=-MWVTO75WC
MT5MJ!9Z'1Q)PZM:FTC'#QM(X;JGTK*UHYPA''6\WXG)7WJ;G_,,5<W57<?V8
MO<CLAN^)K1X$CW22#62/)<]\GPWO<<[GO=BYSB=TG%2NPHFMYXRS;,HLVW>V
MFRT4G_;VU-]M+&0RX4]+<:CJ9&K?\%U%(^2C<P[H+""M-2WH5?F0BWV$^UYO
MS3E\7_LKBM36#R4GN_TMN/@:ZL?YF.T&W:MEU@LFT,+2 \U-&ZWUCFAQQPJ;
M>^*'3(S$PN4JIRRWEP;T7M\R#;>MN;4'A75.M!:UNO;'!>#-W[*?F5V6OU?0
MVNZ6:[6*LKZF"C@F:^&Z6\U-3(R&!CY8>KU43))7@:1A(;CER95!J\MJTXN4
M)*44L=3.GL/6MA=UH4*].I2J3DHIY2CBW@LU@^_ ]'G(2#G&0\:K3L\3A!B<
MH @" H24\$O.11OQW2T8_. TN^LC L)+/2OQT#)$=S A[>X_$]]8&9'2V6=N
M)BDCD&\[%CN_BWOK([2.EHZF'G(9 /T@W2;\YN("#$M\V=8 0! $ 0! $ 0!
M 5XZ:HEYN&1XWPPX?.. 0$A'9JI^60QQ#A.F[N-R=] >N.S&S4XV,M)EDDD.
MLKR0,&,\_J!N8NS#?51=_/EW>1WW(OTRGW_>D;)BHZ6'#5P1@C,XMTWY?E/T
MBHQ;ER@" ( @" ( @" ( @" ( @" ( @*$].RH #B06XZ+AN8[A!R$% 1S[=
M(.0]K^ @M/\ :" MGTT\?*C=Q@:0[HQ0%! $!8OY;O&=[Y0'5 $,K2:DN'G]
M=_C*G_>O4R/"NPYFM^9GVOS(:JN%!1 NJZRFI@!B1-,QKO<9CIN/ !BMBA.7
M"FR-4N*%%8U9QCVOV:3&:O;FR4^(@-37/&Y!$8H\WE)]#)Q K=&UJO3@D5M7
MG=G#@WIRZE@MK,.O&VM9<J>:C@I8:2GG;JY2Y[IYWQDXN8'$1QL#@-QI/"I-
M.VC"2DWBT5-WSBM<TW1A%1IRR?2VO)&%*25 0! $ 0! $ 0! $ 0! $ 0! $
M!J+MI]DZ7_K=)_3UBL.7?/?\+.5]8?I</]9?=D>7B <A (WB,5<'S4^J'Y"B
M3V=;; DD,VTC# 22&-] T!T6@G!K<3F&1<AZB_,0_@]K/T)_9YM\DNT]"NEA
MU?4CH/<RYX^NA $ 0! =FYG^*/IM0'5 $ 0! $ 0! ?.#\W'_LZW_P#B%I_K
MKLNGY1^5?\;\D?#?[C_K\/\ YH?>F>75:' A <M:Y[@QC7/><S&-+WGB:T%Q
M3M,I.3PBFWU&14VQFTUQA?J;341,DAD#9:W1HX\'1N .,Y;(1B=QI6J5>C%Y
MO9F3Z7*.8W$?J4I*+6F7U5XFM;5V#7&0!U[OM)2-W8+9!)5RY\H,]3U>)O 0
MQRD3YE#33BWVY$2V]'5I_6NZT8K5%.7B\/)FV=D.R#8RTWFS3OIJNZ5,-SMT
MC);C5O<QDL=9$]DC*>F%-#BUP!RAV90J]]<3IR2:BL'H.BY=Z8Y5:W-*;C*I
M452.<GECO+H6"/?8@@CTA'!"P$G(V-@W>+$KGG.3TL^O1I4XK",8I=B.LE/3
MRC1E@A>-YT3#_9Q"PI26:;,2I4IK"<8M=A&S6*WRXEC'P'^$\Z/S'Z8'N8+;
M&O-:<R+/EUM/AQCV/V/$BI=FYAB8*F-X_1E:Z-W%BW3;[RVJXB]*:(E3EE19
MTY)]N7TD5-:Z^#$OII"T?&CPE;AO_ +B!Q@+9&I"6AD.I:W%/B@VM:S\BP((
M.!!!&<$8$>X<J]D?JZ0@" ("A)303<Y$QQW]$!WSA@4&!'R6:E?B6.DB/ 0]
MO<=E[Z CI;+4-QU3V2C<!Q8[N'%O?601\M)4P\Y#(T;^CI-^<W%JP"WP.\>X
M@Q*T=//*<(X9'^*QQ'NG# (,42$5FJGY7ED0.^[2(XVM!]]9!(1V6!O.R22<
M P8.]I'OH,R0BHZ6' QP1@CXQ&D[NNTBAC NE@R$!ZG[-?8RU>/7_P!?4JHN
M_GON\D=]R+]+I]_WI&=*,6X0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0%-\4<G
M+8UW"0,>[G0%LZWP//P2Z,G',<1FWCB>^@(&:D>V20-<UV#W#+B#D<1PA 4A
M32'/HCC./O8H"NRE9B-)Q.)&.&09QQE M)XEVOOEW?M%M!2FX5+:>&[W*".&
M)^I8(HZN6-K3J@PO^"T8DDDJ_H4J?PXO#/=7D?)^97MU.]K4W4EN*K))++)2
M>HPLXDEQ)<XYW$DN/&3B2I*262*K#/'I.$ 0! $ 0! $ 0! $ 0! $ 0! $
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M=TS2Z$6'#BO$JM.'$T2:-G=U\Z5.;6O#!;7D972]F]\F;I5$]!1?(?))4/\
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M-*NY1YKE.S9N4>3\G>X%-.9>DXZ-# Z- .C0#HT Z- .C0#HT Z- .C0#HT
MZ- .C0#HT!"[0>KCS'/1<OE9SS/R]_@Q6ZAQE?S+\MT<2[>XPCHU,*(=&@'1
MH"A4<Q-SG-N\T\YS?N/XF]PK*[N\\RT/3HZ-/=UGCWM.\YD]ON=/M3ZKW/-?
M[/ KNUT+Y?\ +I/G_.>-_FO^[PZ"IV7><M]O^7_^9]4<G_B>'?7F[T/Y7\VD
MSR3YB_-:?PN#O/7T'-1<OFV><<__ +;^+^DJ>7=W'?1T+3HZ?:>L^S_V.LOF
M_-3>;\CSJ?E_Q_*?+Q5)<_/EI/H?)?TVGP].C1I?CKZ\3,5H+4( @" ( @"
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g40080tx_pg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40080tx_pg04.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X00Q:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C4M8S R,2 W.2XQ-30Y,3$L(#(P,3,O,3 O,CDM
M,3$Z-#<Z,38@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z,T1%.3 P04,Y14,S,3%%-3@Q0S8Y.$%&.#,Q
M.3$X148B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,T1%.3 P04(Y14,S
M,3%%-3@Q0S8Y.$%&.#,Q.3$X148B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IA,&4Y8F9A-2TQ869A+31E8C8M861F8BTQ
M.&0V-S9F-V1F,F4B('-T4F5F.F1O8W5M96YT240](G5U:60Z.6)A8V4U-&(M
M-#4X92TT-6-D+6%C8F(M9#<Y839D93EB,#8T(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C$V-#0X,SPO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(#$U,3(Q,%].
M;W9O9V5N7T%P<&]I;G1S7T1R7T=A<FYE<E]!<U]#14\N9&]C>#PO<F1F.FQI
M/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \
M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  ^ L8# 1$  A$! Q$!_\0 R@ !  $% 0$! 0            4! P0&!P@"
M"0H! 0 " P$! 0             $!0$#!@('"!   0,#  8' 0D+"P('
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M+6X8)(9HS5CV'I'2"#H(.D'0=*@RBXO=EHT=):NV[UM7;34K<EHT9"P>P@"
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M<)(*F*9KM@>TM-.T;PJLC4CY<?=Q:3"]PVL >/FDE8!AD$&A!!'000>XH"B
M( @" ( @" ( @" ( @" (#U-Z:?P;C?IK_\ U<GFJC+_ %$O0=[P'^60ZY?B
MD;VHQ<&3%9W4WZN"0C:1N-_&?NM0$C%A)W?K98X^H5D/@ /% 2,6'M(R"\R3
M$4-'G=;HZ"UNDCW4!*-:UH#6@-:T4  H !T #4@*H @" ( @" ( @" ( @"
MC,EJA[7^\U 12 ( @" P7_'=_./OH#Y0!#*VG)<E_N%]_G+C^T<I<?"NHYF_
M^IG]Y^LP5[/ 0$1G_P#8\M_D)_R5LM?F1^\0\_\ 17O]MGGY6QPP0! $ 0!
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M?AD>7*5T'2#T*Y/FA^I'V!P!R!SZ  !_S.ST 4'^PVW0N0\Q_J+?W/\ ,S]
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M_24F1PWB&+^HLW(KGI5=JJN\URH-=.K7U=NQ;2%4( @" ( @" ( @" ( @"
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M4#W;R3R/ROZ=\O6G*_*&*BQ6(M'/DX;7/FN;JYEIQKV_NY2Z>\O)RT;SWG4
M  T #G<C(O95UWK\JS?9Z%R'U[A7".'\$PH\/X9;5O&CR;6V]LI-ZRD^5OT4
M6AMBTED$ 0! $!4:CV?=" '6>T^^@*( @+4DT<0&^=)U-&EQUZ:= T=* Q'7
MWR(_=<?N#S0&.ZZF=]]NC8T;OCK0%@N+M+B2=I)/OH"B ("H)&HD=B P)L9C
M+F43W&.L)YQ2DTUE;2RZ-7Z1\3G&G:O2G-*B;IUFF6/CSEOSMP<^=Q3?J,Q^
MB*1HT-$4@#0*- #'4 :*  +$?$NLVO2-%LH<14PYA[0L@( @" ( @" ( @"
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M+CX:$PF8@UK.XO%>CX(#6:.Q8<V^@D0Q+$.2KZ238QD3=V-C(VC[UC6L'<T
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32 4&T>/D@*@"ATC5U[1U(#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
